Latest Industry Insights

In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the biological, clinical and technological frontiers shaping the next generation of ADCs.

In this interview, Technology Networks spoke with Dr. Francesco Dell’Accio and Dr. Suzanne Eldridge to explore the impact of osteoarthritis on patients, the goals of ReFleks and a novel approach to repairing osteochondral defects.

In this interview, Sebastiaan J. Trietsch, Chief Technology Officer at MIMETAS, discusses how microphysiological systems are advancing drug discovery through scalable human-relevant models and AI integration.

In this interview, Technology Networks talked to Dr. Stacy Lindborg, president, chief executive officer and board member at IMUNON, Inc., who shares how its PlaCCine® platform could reshape vaccine development.

We spoke with Dr. Michael Gonzales to learn more about the UKB-PPP and its goals, the technical hurdles of large-scale proteomics and how Olink technology is helping to overcome them.

In this interview, Dr. Christian Schafmeister discusses the structural advantages of Spiroligomer molecules, their ability to disrupt protein–protein interactions and their potential applications in cancer therapy and beyond.

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and innovative manufacturing strategies are overcoming the key limitations of autologous CAR T-cell therapy.

A specialist in flow cytometry, cell sorting and cellular biology, Dr. Richard Cuthbert shared his perspectives on the current and future applications of flow cytometry – and automated flow cytometry systems – in modern drug discovery.

Dr. Bo Wiinberg, chief business development officer at the Novo Nordisk Foundation Cellerator, discusses the current obstacles halting advances in stem cell-based cell therapies and what can be done to overcome them.

bit.bio’s GFP ioMicroglia enables real-time tracking of microglia in complex co-cultures and in vivo, streamlining neurodegeneration research and drug discovery.